Posts by cowic

13th of July is GIST Awareness Day, and SPAEN is encouraging everyone to help bring attention to GIST and other rare cancers. The theme of GIST Awareness Day this year is HOPE! 2020 brought a global health crisis that has challenged GIST patients. This year’s GIST Awareness Day is dedicated to Nikhil Guhagarkar, our beloved…

July is the month of #SarcomaAwareness! We at SPAEN fight for a better situation for sarcoma, GIST, bonecancer and desmoid patients – together with our member groups, patients & advocates, experts & healthcare professionals. Stronger together!! We are here for you!    “Sarcoma Awareness Month 2020” What are sarcomas? A sarcoma is a cancer which…

COVID-19 and the fact that you as cancer patients and survivors are considered a “risk group” causes a lot of uncertainties: A lot of you feel left alone with your fears and questions. However, many of our national patient advocacy groups for sarcoma, GIST and desmoid patients keep on providing support and information to you…

The constant news about the coronavirus can be worrying, especially for people with cancer and their families. Cancer and its treatment can lower your ability to fight infection. We have therefore put together information and resources about the coronavirus in general and especially for cancer patients, including specific (though very limited) information for sarcoma and GIST…

Medical societies such as the European Society of Medical Oncology (ESMO) in Europe or the National Comprehensive Cancer Network (NCCN) create guidelines which outline the standards of care for different types of cancer – among them guidelines for soft tissue sarcoma, bone sarcoma and GIST. These guidelines provide recommendations about diagnosis, treatment and follow-up for…

European Commission Grants Lilly’s olaratumab (LARTRUVOTM), in Combination with Doxorubicin, Approval for the Treatment of Advanced Soft Tissue Sarcoma in Europe Olaratumab, in combination with doxorubicin, is the first front-line therapy approved in four decades for advanced soft tissue sarcoma in Europe JGDG study showed olaratumab, in combination with doxorubicin, offered a median 11.8-month increase…

Ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. HOW MANY patients participated? A total of 946 patients at 56 centers in 13 countries in Europe and Australia/New Zealand/Singapore took part…

The following table lists the results of some of the many clinical trials available worldwide for sarcoma, GIST or desmoid patients. For more information about some of the ongoing trials, click here. No Trial Name Agents Phase Status Results Sponsor 1 Study 62005 Imatinib in twodifferent dosings III Closed Results Study 62005 EORTC Note: The…

Clinical studies are an essential step in the development of novel treatment methods for cancer and other diseases. They show researchers what works for the welfare of patients and what does not. In addition to safety and effectiveness they also determine whether the side effects of a new treatment are acceptable and, increasingly, what quality…

Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnershipPublished in ESMO Open, June 2022 Research in sarcomas has historically been the domain of scientists and clinicians attempting to understand the disease to develop effective treatments. This traditional approach of placing scientific…